Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Cardiology
CLL
Questions discussed in this category
For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?
Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...
5 Answers available
What is your approach to CLL in patients with atrial fibrillation and/or on anticoagulation?
Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...
3 Answers available
1424
10579
Papers discussed in this category
The New England journal of medicine, 2015-12-17
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Blood, 2022 Jul 14
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Leukemia, 2021 Apr 27
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
J Am Coll Cardiol, 2019 Oct 01
Cardiovascular Toxicities Associated With Ibrutinib.
Related Topics in Cardiology
Lung Cancer
Breast Cancer
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Gastrointestinal Cancers
Genitourinary Cancers
Pediatric Hematology/Oncology
Radiation Physics